JGJoan Gil

Joan Gil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joan Gil has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes

    by Matthew P. Lennol, Nicholas J. Ashton, Oscar Moreno-Pérez, María-Salud García-Ayllón, Jose-Manuel Ramos-Rincon, Mariano Andrés, José-Manuel León-Ramírez, Vicente Boix, Joan Gil, Kaj Blennow, et al.

    The levels of several glial and neuronal plasma biomarkers have been found to increase during the acute phase in COVID-19 patients with neurological symptoms. However, replications in patients with minor or non-neurological symptoms are needed to understand their potential as indicators of CNS injury or vulnerability. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain protein (NfL), and total Tau (T-tau) were determined by Single molecule array (Simoa) immunoassays in 45 samples from COVID-19 patients in the acute phase of infection [moderate (n = 35), or severe (n = 10)] with minor or non-neurological symptoms; in 26 samples from fully recovered patients after ~2 months of clinical follow-up [moderate (n = 23), or severe (n = 3)]; and in 14 non-infected controls. Plasma levels of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), were also determined by Western blot. Patients with COVID-19 without substantial neurological symptoms had significantly higher plasma concentrations of GFAP, a marker of astrocytic activation/injury, and of NfL and T-tau, markers of axonal damage and neuronal degeneration, compared with controls. All these biomarkers were correlated in COVID-19 patients at the acute phase. Plasma GFAP, NfL and T-tau levels were all normalized after recovery. Recovery was also observed in the return to normal values of the quotient between the ACE2 fragment and circulating full-length species, following the change noticed in the acute phase of infection. None of these biomarkers displayed differences in plasma samples at the acute phase or recovery when the COVID-19 subjects were sub-grouped according to occurrence of minor symptoms at re-evaluation 3 months after the acute episode (so called post-COVID or “long COVID”), such as asthenia, myalgia/arthralgia, anosmia/ageusia, vision impairment, headache or memory loss. Our study demonstrated altered plasma GFAP, NfL and T-tau levels in COVID-19 patients without substantial neurological manifestation at the acute phase of the disease, providing a suitable indication of CNS vulnerability; but these biomarkers fail to predict the occurrence of delayed minor neurological symptoms.


  • Open Access

    Impact of COVID-19 on Health-Related Quality of Life: A Longitudinal Study in a Spanish Clinical Sample

    by Irene Rodríguez-Galán, Natalia Albaladejo-Blázquez, Nicolás Ruiz-Robledillo, José Francisco Pascual-Lledó, Rosario Ferrer-Cascales, Joan Gil-Carbonell

    SARS-CoV-2 respiratory infection and the course of its sequelae remain to be defined. The aim of this study is to analyze health status and Health-Related Quality of Life (HRQoL) in a Spanish sample of survivors of coronavirus disease 2019 (COVID-19) pneumonia. Methods: Prospective observational study of patients who survived SARS-CoV-2 pneumonia, between February 2020 and May 2020, with systematic evaluation at 3 and 12 months after the onset of the disease. The data were obtained by reviewing the clinical history and performing a physical examination, a chest X-ray, and a pulmonary function test on the patients. Additionally, the SF-36 questionnaire was administered for the HRQoL study. Results: In total, 130 patients aged 55.9 ± 15.9 years were included. Dyspnea (36.9%) and asthenia (36.2%) were the most frequent persistent symptoms. Fibrotic pulmonary changes were detected in 20.8% of the participants. Compared to the general population, significant deterioration was detected in all domains of the SF-36 questionnaire at 3 and 12 months post-COVID-19 infection. The greatest differences were in the physical role (RF) and in the emotional role (RE). Conclusions: COVID-19 pneumonia causes a long-term deterioration in HRQoL compared to the general population. Over time, a trend toward improvement is detected in most domains of the SF-36.


  • Open Access

    Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors

    by Vega Jovani, Irene Calabuig, Maria Luisa Peral-Garrido, Ernesto Tovar-Sugrañes, María-Del-Carmen López-González, Pilar Bernabeu, Agustín Martínez, Joaquim Esteve-Vives, Jose-Manuel León-Ramírez, Oscar Moreno-Perez, et al.


  • Open Access

    Latin American Origin Is Not Associated with Worse Outcomes among Hospitalized Patients with COVID-19 in a Public Healthcare System

    by Silvia Otero-Rodriguez, Oscar Moreno-Pérez, Jose Manuel Ramos, Mar García, Vicente Boix, Sergio Reus, Diego Torrus, Pablo Chico-Sánchez, José Sánchez-Payá, Fernando Aldana-Macias, et al.

    Exploring differences in clinical outcomes based on race and origin among patients hospitalized for COVID-19 is a controversial issue. The ALC COVID-19 Registry includes all confirmed COVID-19 patients admitted to hospital from 3 March 2020 to 17 December 2020. The data were obtained from electronic health records in order to evaluate the differences in the clinical features and outcomes among European and Latin American patients. The follow-ups occurred after 156 days. A propensity score weighting (PSW) logistic regression model was used to estimate the odds ratio (OR, 95% CI) for Latin American origin and outcome associations. Of the 696 patients included, 46.7% were women, with a median age of 65 (IQR 53–67) years, 614 (88.2%) were European, and 82 (11.8%) were Latin American. Latin American patients were younger, with fewer comorbidities, and a higher incidence of extensive pneumonia. After adjusting for residual confounders, Latin American origin was not associated with an increased risk of death (PSW OR 0.85 (0.23–3.14)) or with the need for invasive mechanical ventilation (PSW OR 0.35 (0.12–1.03)). Latin American origin was associated with a shorter hospital stay, but without differences in how long the patient remained on mechanical ventilation. In a public healthcare system, the rates of death or mechanical ventilation in severe COVID-19 cases were found to be comparable between patients of European and Latin American origins.


  • Open Access

    Male pituitary–gonadal axis dysfunction in post‐acute COVID‐19 syndrome—Prevalence and associated factors: A Mediterranean case series

    by Oscar Moreno-Perez, Esperanza Merino, Rocio Alfayate, Maria Eugenia Torregrosa, Mariano Andres, Jose-Manuel Leon-Ramirez, Vicente Boix, Joan Gil, Antonio Pico

    Objective: Severe acute respiratory syndrome coronavirus 2 through angiotensin‐converting enzyme 2 receptor can harm testes function. The objectives were to analyse the prevalence of low serum testosterone (LT) and impaired fertility potential (Leydig and Sertoli cells dysfunction, respectively) in coronavirus disease 2019 (COVID‐19) male survivors and to evaluate acute infection‐related associated factors. Also, we explore its association with post‐acute COVID‐19 syndrome (PCS) and quality of life (QOL).Materials and Methods: Male adults recovered from polymerase chain reaction‐confirmed COVID‐19 were offered a structured evaluation 8–12 weeks after recovery. The main outcome measure(s) were as follows: LT, defined as total testosterone (TT) < 2 ng/ml or if TT levels 2–4 ng/ml as calculated free testosterone < 6.36 ng/dl; Sertoli cell dysfunction was defined as inhibin‐B < 89 pg/ml. Secondary outcome‐associated factors were analysed by multiple logistic regression (odds ratio; 95% confidence interval [CI]). QOL was evaluated by SF‐36 v.2.Results: One hundred and forty‐three patients were evaluated at a median (interquartile range) of 77 days (72–83) after disease onset; 72% of them recovered from severe pneumonia. LT was detected in 41 patients (28.7%; 95% CI: 21.8–36.5). Low levels of inhibin‐B were detected in 25 patients (18.1%; 95% CI: 12.5–25.3). After multivariate adjustment, obesity and hypokalaemia were associated with LT, whereas age more than 65 was an independent predictor of Sertoli cell dysfunction. LT or Sertoli cell dysfunction was not associated with PCS. Patients with LT had a lower score in four domains of QOL.Conclusions: Prevalence of male LT and impaired fertility potential in COVID‐19 survivors is high in the medium term. Traditional risk factors and severity markers for COVID‐19 could be predictive.


  • Open Access

    Clinical Frailty Score vs Hospital Frailty Risk Score for predicting mortality and other adverse outcome in hospitalised patients with COVID‐19: Spanish case series

    by Jose-Manuel Ramos-Rincon, Oscar Moreno-Perez, Hector Pinargote-Celorio, Jose-Manuel Leon-Ramirez, Mariano Andres, Sergio Reus, Cristian Herrera-García, Ana Martí-Pastor, Vicente Boix, Joan Gil, et al.

    Objectives Frailty can be used as a predictor of adverse outcomes in people with coronavirus disease 2019 (COVID-19). The aim of the study was to analyse the prognostic value of two different frailty scores in patients hospitalised for COVID-19. Material and Methods This retrospective cohort study included adult (≥18 years) inpatients with COVID-19 and took place from 3 March to 2 May 2020. Patients were categorised by Clinical Frailty Score (CFS) and Hospital Frailty Risk Score (HFRS). The primary outcome was in-hospital mortality, and secondary outcomes were tocilizumab treatment, length of hospital stay, admission in intensive care unit (ICU) and need for invasive mechanical ventilation. Results were analysed by multivariable logistic regression and expressed as odds ratios (ORs), adjusting for age, sex, kidney function and comorbidity. Results Of the 290 included patients, 54 were frail according to the CFS (≥5 points; prevalence 18.6%, 95% confidence interval [CI]: 14.4-23.7) vs 65 by HFRS (≥5 points; prevalence: 22.4%, 95% CI 17.8-27.7). Prevalence of frailty increased with age according to both measures: 50-64 years, CFS 1.9% vs HFRS 12.3%; 65-79 years, CFS 31.5% vs HFRS 40.0%; and ≥80 years, CFS 66.7% vs HFRS 40.0% (P < .001). CFS-defined frailty was independently associated with risk of death (OR 3.67, 95% CI 1.49-9.04) and less treatment with tocilizumab (OR 0.28, 95% CI 0.08-0.93). HFRS-defined frailty was independently associated with length of hospital stay over 10 days (OR 2.89, 95% CI 1.53-5.44), ICU admission (OR 4.18, 95% CI 1.84-9.52) and invasive mechanical ventilation (OR 5.93, 95% CI 2.33-15.10). Conclusion In the spring 2020 wave of the COVID-19 pandemic in Spain, CFS-defined frailty was an independent predictor for death, while frailty as measured by the HFRS was associated with length of hospital stay over 10 days, ICU admission and use of invasive mechanical ventilation.


  • Open Access

    Medium‐term serostatus in Spanish case series recovered from SARS‐CoV‐2 infection

    by Oscar Moreno‐Pérez, Jose Manuel Ramos, Adelina Gimeno, Juan Carlos Rodríguez, Mariano Andres, Jose‐Manuel Leon‐Ramirez, Beatriz Valero, Pere Llorens, Vicente Boix, Joan Gil, et al.

    The medium‐term serologic response of SARS‐CoV‐2 infection recovered individuals is not well known. The aims were to quantify the incidence of seropositive failure in the medium term in a cohort of patients with different COVID‐19 severity and to analyze its associated factors. Patients who had recovered from mild and severe forms of SARS‐CoV‐2 infection in an Academic Spanish hospital (March 12–May 2, 2020), were tested for total anti‐SARS‐CoV‐2 antibodies by electrochemiluminescence immunoassay (Elecsys Anti‐SARS‐CoV‐2 test; Roche Diagnostics GmbH). The non‐seropositive status (seropositive failure) incidence (95% CI) was determined. Associations were tested by multiple logistic regression in a global cohort and severe pneumonia subpopulation. Of 435 patients with PCR‐confirmed SARS‐CoV‐2, a serological test was carried out in 325: 210 (64.6%) had severe pneumonia (hospitalized patients), 51 (15.7%) non‐severe pneumonia (managed as outpatients), and 64 (19.7%) mild cases without pneumonia. After a median (IQR) of 76 days (70–83) from symptom onset, antibody responses may not consistently develop or reach levels sufficient to be detectable by antibody tests (non‐seropositive incidence) in 6.9% (95% CI, 4.4–10.6) and 20.3% (95% CI, 12.2–31.7) of patients with and without pneumonia, respectively. Baseline independent predictors of seropositive failure were higher leukocytes and fewer days of symptoms before admission, while low glomerular filtrate and fever seem associated with serologic response. Age, comorbidity or immunosuppressive therapies (corticosteroids, tocilizumab) did not influence antibody response. In the medium‐term, SARS‐CoV‐2 seropositive failure is not infrequent in COVID‐19 recovered patients. Age, comorbidity or immunosuppressive therapies did not influence antibody response.

  • Open Access

    Fatality and risk features for prognosis in COVID-19 according to the care approach – a retrospective cohort study

    by Mariano Andrés, Jose-Manuel Leon-Ramirez, Oscar Moreno-Perez, José Sánchez-Payá, Ignacio Gayá, Violeta Esteban, Isabel Ribes, Diego Torrus-Tendero, Pilar González-De-La-Aleja, Pere Llorens, et al.

    Introduction: This study analyzed the impact of a categorized approach, based on patients’ prognosis, on major outcomes and explanators in patients hospitalized for COVID-19 pneumonia in an academic center in Spain.Methods: Retrospective cohort study (March 3 to May 2, 2020). Patients were categorized according to the followed clinical management, as maximum care or limited therapeutic effort (LTE). Main outcomes were all-cause mortality and need for invasive mechanical ventilation (IMV). Baseline factors associated with outcomes were analyzed by multiple logistic regression, estimating odds ratios (OR; 95%CI).Results: Thirty-hundred and six patients were hospitalized, median age 65.0 years, 57.8% males, 53.3% Charlson index ≥3. The overall all-cause fatality rate was 15.0% (n = 46). Maximum care was provided in 238 (77.8%), IMV was used in 38 patients (16.0%), and 5.5% died. LTE was decided in 68 patients (22.2%), none received IMV and fatality was 48.5%. Independent risk factors of mortality under maximum care were lymphocytes 15ng/L and hypotension. Advanced age, lymphocytes 240pg/mL independently associated with IMV requirement.Conclusion: Overall fatality in the cohort was 15% but markedly varied regarding the decided approach (maximum care versus LTE), translating into nine-fold higher mortality and different risk factors.


  • Top Cited Papers

    Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study

    by Oscar Moreno-Pérez, Esperanza Merino, Jose-Manuel Leon-Ramirez, Mariano Andres, Jose Manuel Ramos, Juan Arenas-Jiménez, Santos Asensio, Rosa Sanchez, Paloma Ruiz-Torregrosa, Irene Galan, et al.


  • Open Access

    Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients

    by Oscar Moreno-Pérez, Jose-Manuel Leon-Ramirez, Laura Fuertes-Kenneally, Miguel Perdiguero, Mariano Andres, Mar Garcia-Navarro, Paloma Ruiz-Torregrosa, Vicente Boix, Joan Gil, Esperanza Merino, et al.